Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

vobramitamab duocarmazine (MGC018)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Byondis, MacroGenics

Drug class:

DNA replication inhibitor, B7-H3-targeted antibody-drug conjugate

Related drugs:

›

CD276 expression	Head and Neck Cancer	CD276 expression	Head and Neck Cancer	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D
CD276 expression	Breast Cancer	CD276 expression	Breast Cancer	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D
CD276 overexpression	Squamous Cell Carcinoma of Head and Neck	CD276 overexpression	Squamous Cell Carcinoma of Head and Neck	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D
CD276 expression	Prostate Cancer	CD276 expression	Prostate Cancer	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D
CD276 expression	Neuroblastoma	CD276 expression	Neuroblastoma	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D